| Literature DB >> 30881464 |
Sangita Thapa1, Lokendra Bahadur Sapkota2.
Abstract
BACKGROUND: Neonatal septicemia is one of the most common leading reasons for neonatal morbidity and mortality in developing countries. Frequent monitoring on pathogens with recent updates and their antimicrobial sensitivity pattern is mandatory for the better treatment. The aim of the study was to determine the bacteriological profile of neonatal septicemia and their antibiotic susceptibility pattern.Entities:
Year: 2019 PMID: 30881464 PMCID: PMC6381565 DOI: 10.1155/2019/3784529
Source DB: PubMed Journal: Int J Pediatr ISSN: 1687-9740
Distribution of organisms isolated from blood culture in neonatal septicemia.
|
|
|
| |
|---|---|---|---|
|
|
| ||
|
| |||
|
| |||
|
| 4 (7.1) | 1 (1.7) | 5 (8.9) |
|
| 2 (3.5) | 3 (5.3) | 5 (8.9) |
|
| 3 (5.3) | 1 (1.7) | 4 (7.1) |
|
| 1 (1.7) | 1 (1.7) | 2 (3.5) |
|
| 0 | 2 (3.5) | 2 (3.5) |
|
| |||
|
| 14 (25.0) | 4 (7.1) | 18 (32.1) |
|
| 2 (3.5) | 1 (1.7) | 3 (5.3) |
|
| |||
|
| 9 (16.0) | 2 (3.5) | 11 (19.6) |
| CONS | 2 (3.5) | 4 (7.1) | 6 (11.1) |
|
|
|
|
|
CONS: coagulase negative staphylococci. Figure in parenthesis indicates percentage.
Causative organisms of EOS and LOS.
|
|
|
| |
|---|---|---|---|
|
|
| ||
|
| |||
|
| |||
|
| 3 (5.3) | 2 (3.5) | 5 (8.9) |
|
| 3 (5.3) | 2 (3.5) | 5 (8.9) |
|
| 1 (1.7) | 3 (5.3) | 4 (7.1) |
|
| 2 (3.5) | 0 | 2 (3.5) |
|
| 2 (3.5) | 0 | 2 (3.5) |
|
| |||
|
| 13 (23.2) | 5 (8.9) | 18 (32.1) |
|
| 1 (1.7) | 2 (3.5) | 3 (5.3) |
|
| |||
|
| 9 (16.0) | 11 (19.6) | 11 (19.6) |
| CONS | 1 (1.7) | 5 (8.9) | 6 (11.1) |
|
|
|
|
|
LOS: late onset septicemia, EOS: early onset septicemia, and CONS: coagulase negative staphylococci. Figure in parenthesis indicates percentage.
Antibiotic sensitivity profile of gram-positive and gram-negative isolates.
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| A/s | 18.1 | NT | 0 | 100 | 100 |
| AK | 90.9 | 100 | 16.6 | 94.4 | 100 |
| CTR | 0 | 83.3 | 22.2 | 11.1 | 100 |
| CTX | 18.1 | 83.3 | 16.6 | 11.1 | NT |
| COT | 81.8 | 33.3 | 22.2 | 72.2 | 0 |
| CD | 72.7 | 0 | NT | NT | NT |
| CX | 36.3 | 66.6 | NT | NT | NT |
| CFM | 18.1 | 50.0 | 27.7 | 5.5 | 100 |
| COX | 63.6 | 0 | NT | NT | NT |
| E | 72.7 | 0 | NT | NT | NT |
| GEN | NT | 0 | 100 | 88.8 | NT |
| MRP | 81.8 | 66.6 | 100 | 94.4 | 100 |
| NA | 9.0 | NT | 22.2 | 66.6 | NT |
| OF | 54.5 | 66.6 | 100 | 88.8 | 100 |
| PIT | 18.1 | 100 | 27.7 | 100 | 100 |
| TEI | 90.9 | 100 | NT | NT | NT |
| VA | 100 | 100 | NT | NT | NT |
Figures depict percentage, CONS: Coagulase negative staphylococci, NT: not tested, A/S: ampicillin/sulbactam, AK: amikacin, CTR: ceftriaxone, CTX: cefotaxime, COT: cotrimoxazole, CD: clindamycin, CX: cefoxitin, CFM: cefixime, COX: cloxacillin, E: erythromycin, GEN: gentamicin, MRP: meropenem, NA: nalidixic acid, OF: ofloxacin, PIT: piperacillin/tazobactam, TEI: teicoplanin, and VA: vancomycin.